[1] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79(6): 1542-1556.
[2] Younossi ZM, Golabi P, Paik JM. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347.
[3] Yip TCF, Fan JG, Wong VWS. China’s Fatty Liver Crisis: A Looming Public Health Emergency[J]. Gastroenterology, 2023, 165(4): 825-827.
[4] Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD[J]. J Hepatol, 2024, 80(2): e62-e64.
[5] Tsochatzis EA. Natural history of NAFLD: knowns and unknowns[J]. Nat Rev Gastroenterol Hepatol, 2021, 19(3): 151-152.
[6] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.
[7] Taylor RS, Taylor RJ, Bayliss S, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis[J]. Gastroenterology, 2020, 158(6): 1611-1625.e1612.
[8] Li J, Delamarre A, Wong VWS, et al. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease[J]. United Eur Gastroenterol J, 2023, 12(2): 219-225.
[9] Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2021, 75(4): 786-794.
[10] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[11] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update[J]. J Hepatol, 2021, 75(3): 659-689.
[12] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. Endocr Pract, 2022, 28(5): 528-562.
[13] Boursier J, Hagström H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events[J]. J Hepatol, 2022, 76(5): 1013-1020.
[14] Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy[J]. Hepatology, 2016, 63(6): 1817-1827.
[15] Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis[J]. J Hepatol, 2021, 75(4): 770-785.
[16] Canivet CM, Costentin C, Irvine KM, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD[J]. Hepatology, 2023, 77(3): 920-930.
[17] Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4): 362-373.
[18] Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores[J]. J Hepatol, 2023, 78(2): 247-259.
[19] Lin H, Lee HW, Yip TC-F, et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease[J]. JAMA, 2024,331(15):1287-1297.
[20] Younossi ZM. Predicting Liver-Related Outcomes in Steatotic Liver Disease[J]. JAMA, 2024, 331(15):1274-1275. |
